Rangel, Jose David Gomez
2 papers on CoChat
Most cited papers
- Verified
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial
Kelley, R. K., Rimassa, L., Cheng, A.-L., Kaseb, A., Qin, S., Zhu, A. X., Chan, S. L., Melkadze, T., Sukeepaisarnjaroen, W., Breder, V., et al. (2022) · The Lancet Oncology
Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers
Cited by 535
- Verified
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study
Yau, T., Kaseb, A., Cheng, A.-L., Qin, S., Zhu, A. X., Chan, S. L., Melkadze, T., Sukeepaisarnjaroen, W., Breder, V., Verset, G., et al. (2024) · The Lancet Gastroenterology & Hepatology
Hepatocellular Carcinoma Treatment and PrognosisColorectal Cancer Treatments and Studies
Cited by 97
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free